2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!

Acute and Chronic Leukemias

Capsule Summary Slidesets

New data for CC-486 maintenance therapy in AML support a new escalated 21-day dosing schedule for patients who experience relapse with ≤ 15% blasts and an overall preservation of health-related quality of life.

Released: December 9, 2020

FLT3 inhibitor gilteritinib combined with induction and consolidation chemotherapy was well tolerated and showed good response in final results from this phase I study of patients with newly diagnosed FLT3-mutated acute myeloid leukemia.

Released: December 7, 2020

The combination of magrolimab plus azacytidine was associated with rapid, deep responses with little added toxicity, including in patients with the TP53 mutation.

Released: December 7, 2020

In a phase I/II trial, flotetuzumab showed encouraging activity and a manageable safety profile in patients with AML and primary induction failure or early relapse.

Released: December 15, 2020

Hyper-CVAD + blinatumomab shows promising activity with both high response rates and deep responses in patients with newly diagnosed B-cell ALL in this phase II study.

Released: December 11, 2020

In an interim analysis of the randomized phase II OPTIC trial, the maximum benefit:risk ratio with ponatinib was observed with 45-mg starting dose in previously treated CP-CML regardless of mutation status or number of previous TKIs.

Released: December 10, 2020

Ponatinib treatment in patient with chronic-phase chronic myeloid leukemia who progressed after second-generation TKIs showed efficacy and tolerability in this pooled analysis of the PACE and OPTIC trials.

Released: December 15, 2020

Twice-daily asciminib was associated with a major molecular response rate of 46.9% in pretreated patients with T315I-mutated CML, including those previously treated with ponatinib.

Released: December 16, 2020

Oral AZA (CC-486) significantly improved OS and RFS in patients with CR/CRi AML regardless of baseline MRD status, although baseline MRD positivity showed reduced benefit.

Released: December 14, 2020

At Week 24, asciminib significantly improved MMR rate compared with bosutinib (25.5% vs 13.2%, respectively) with numerically lower rates of AEs leading to discontinuation, dose adjustment, or the requirement for additional therapy.

Released: December 14, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue